INFIライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 9月 2023 @ 04:59):

Stats
本日の出来高	2.48M
平均出来高	3.98M
時価総額	726 089
EPS	$0 ( 2024-03-26 )
次の収益日	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0182
ATR14	$0.00900 (230.77%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-09	Perkins Adelene Q	Buy	768 133	Common Stock
2023-09-12	Perkins Adelene Q	Sell	410 196	Common Stock
2023-09-09	Perkins Adelene Q	Sell	768 133	Restricted Stock Unit
2022-08-02	Peluso Stephane	Buy	14 994	Common Stock
2022-08-02	Peluso Stephane	Sell	50 000	Restricted Stock Unit

INSIDER POWER
-16.99
Last 96 transactions
Buy: 10 433 668 \| Sell: 9 549 867

ボリューム相関

長: 0.01 (neutral)

短: 0.15 (neutral)

Signal:(27.787) Neutral

Infinity Pharmaceuticals 相関

10 最も正の相関
TTOO	0.944
IMPL	0.942
VNET	0.938
AVIR	0.933
EGAN	0.931
STAF	0.924
TUEM	0.924
AZYO	0.921
JD	0.92
BGFV	0.92

10 最も負の相関
TA	-0.959
TYHT	-0.937
SERA	-0.936
SYKE	-0.933
RDUS	-0.927
CPTA	-0.924
XLRN	-0.923
ICON	-0.923
ZGNX	-0.92
PAE	-0.915

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Infinity Pharmaceuticals 相関 - 通貨/商品

0.29
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.11
( neutral )

0.44
( neutral )

-0.28
( neutral )

Infinity Pharmaceuticals 財務諸表

Annual	2022
収益:	$2.59M
総利益:	$1.03M (39.72 %)
EPS:	$-0.480

FY	2022
収益:	$2.59M
総利益:	$1.03M (39.72 %)
EPS:	$-0.480

FY	2021
収益:	$1.86M
総利益:	$738 000 (39.72 %)
EPS:	$-0.530

FY	2020
収益:	$1.72M
総利益:	$682 000 (39.67 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.